**Summary of Croda International PLCs Final Results for the Year Ended 31 December 2025**
Croda International PLC, a leading specialty chemicals company, announced its final results for the year ended 31 December 2025, highlighting encouraging progress in delivering its growth and returns strategy despite an uncertain trading environment.
**Financial Highlights**
**Sales Growth** Group sales increased by 4.4% to ยฃ1,699.4 million, with a 6.6% growth at constant currency. Consumer Care and Life Sciences segments led the growth, with sales up 8% in both segments.
**Adjusted Operating Profit** Adjusted operating profit rose by 7.9% to ยฃ295.3 million at constant currency, driven by improved profitability in Consumer Care and Life Sciences.
**Adjusted Profit Before Tax** Adjusted profit before tax increased by 8.4% to ยฃ276.2 million, or ยฃ282.0 million at constant currency.
**Dividend** The full-year dividend was increased by 1p to 111p per share.
**Business Performance**
**Consumer Care** Sales grew by 8% at constant currency, with strong performance in Fragrances and Flavours (F&F), Beauty Actives, and Beauty Care.
**Life Sciences** Sales increased by 8% at constant currency, driven by growth in Crop Protection and Pharma.
**Industrial Specialties** Sales declined by 2% at constant currency due to lower sales volumes.
**Strategic Progress**
**Innovation** Croda refocused its innovation efforts, introducing a new rigorous framework and reallocating R&D resources to prioritize customer-centric innovation.
**Customer Experience** The company improved customer experience through tailored solutions, bespoke service packages, and regionalization of claims testing and formulation support.
**Transformation Program** Crodas transformation program delivered ยฃ28 million in gross benefits in 2025, with a target of ยฃ100 million in total annualized benefits by 2028.
**Financial Framework to 2028**
Croda set out a new financial framework to 2028, targeting
**Sales Growth** 3-6% organic sales growth CAGR
**Adjusted Operating Margin** >20% by 2028
**Free Cash Flow-to-Sales Ratio** >12% by 2028
**Return on Invested Capital (ROIC)** >10% by 2028
**2026 Outlook**
For 2026Croda expects
**Group Organic Sales Growth** Within the 3-6% range
**Adjusted Operating Margin** Further increase driven by improving profitability in Consumer Care and Life Sciences
**Adjusted Operating Profit** In line with current market expectations at constant currency
**Conclusion**
Croda International PLC demonstrated resilience and progress in 2025, delivering sales growth, improved profitability, and strategic advancements despite market challenges. The companys financial framework to 2028 and 2026 outlook reflect its confidence in achieving sustainable growth, enhanced profitability, and improved returns on capital.
Here is an HTML table comparing the financials and debt year on year for Croda International PLC based on the provided text:
**Key Observations:** * **Sales Growth:** Croda International PLC experienced a 4.4% increase in sales from 2024 to 2025, reaching ยฃ1,699.4 million.
* **EBITDA and Operating Profit:** Both EBITDA and operating profit showed growth, with EBITDA increasing by 5.0% and operating profit by 5.6%.
* **Profit Before Tax:** Profit before tax also increased by 6.2%, indicating improved profitability.
* **Free Cash Flow:** Free cash flow decreased slightly by 4.7%, but remained positive at ยฃ161.6 million.
* **Net Debt Reduction:** The company successfully reduced its net debt by 1.6%, from ยฃ532.3 million in 2024 to ยฃ523.8 million in 2025. This table provides a concise overview of Croda International PLC's financial performance and debt position, highlighting areas of growth and improvement.